Coombe Bender & Co LLC Buys Shares of 11,584 Pfizer Inc. (NYSE:PFE)

Coombe Bender & Co LLC bought a new position in Pfizer Inc. (NYSE:PFE) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 11,584 shares of the biopharmaceutical company’s stock, valued at approximately $334,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Xponance Inc. raised its stake in Pfizer by 8.3% during the third quarter. Xponance Inc. now owns 799,181 shares of the biopharmaceutical company’s stock worth $26,509,000 after buying an additional 61,069 shares during the last quarter. Joel Isaacson & Co. LLC boosted its position in shares of Pfizer by 1.5% during the 3rd quarter. Joel Isaacson & Co. LLC now owns 50,086 shares of the biopharmaceutical company’s stock valued at $1,661,000 after purchasing an additional 718 shares in the last quarter. Clear Creek Financial Management LLC grew its stake in Pfizer by 32.0% during the third quarter. Clear Creek Financial Management LLC now owns 29,026 shares of the biopharmaceutical company’s stock worth $964,000 after purchasing an additional 7,044 shares during the period. Austin Asset Management Co Inc bought a new stake in Pfizer in the third quarter worth approximately $224,000. Finally, Bridgeworth LLC grew its holdings in Pfizer by 7.3% in the third quarter. Bridgeworth LLC now owns 14,552 shares of the biopharmaceutical company’s stock worth $483,000 after purchasing an additional 989 shares during the period. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the company. Guggenheim began coverage on Pfizer in a report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target on the stock. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 price target (up from $33.00) on shares of Pfizer in a report on Thursday. Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price for the company. in a research report on Thursday, January 4th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Eleven research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $36.53.

Pfizer Stock Performance

Shares of NYSE:PFE traded up $0.70 during midday trading on Thursday, reaching $27.88. 32,050,252 shares of the company’s stock traded hands, compared to its average volume of 42,426,480. Pfizer Inc. has a one year low of $25.20 and a one year high of $40.37. The stock has a 50 day moving average of $26.87 and a 200 day moving average of $28.25. The company has a market cap of $157.87 billion, a price-to-earnings ratio of 76.89, a P/E/G ratio of 1.15 and a beta of 0.63. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. The firm had revenue of $14.88 billion during the quarter, compared to analyst estimates of $13.87 billion. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The business’s revenue for the quarter was down 19.5% on a year-over-year basis. During the same period in the previous year, the business posted $1.23 earnings per share. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 10th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 6.03%. The ex-dividend date is Thursday, May 9th. Pfizer’s payout ratio is currently 466.67%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.